WEKO3
アイテム
Carbon Ion Radiotherapy for Bone and Soft Tissue Sarcomas
https://repo.qst.go.jp/records/71357
https://repo.qst.go.jp/records/71357e5f4b2ac-f90f-4db0-aa55-e083da5d2692
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2013-11-14 | |||||
タイトル | ||||||
タイトル | Carbon Ion Radiotherapy for Bone and Soft Tissue Sarcomas | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Kamada, Tadashi
× Kamada, Tadashi× Imai, Reiko× Tsujii, Hirohiko× Serizawa, Itsuko× 鎌田 正× 今井 礼子× 辻井 博彦× 芹澤 慈子 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background: Carbon ion radiotherapy showed promising clinical outcomes in 57 patients with bone and STS during the phase I study (Kamada, JCO 22 4466-4471, 2002). This phase II study was planned thereafter. Methods: From April 2000 to February 2007, 301 lesions of 282 patients with bone and STS not suited for surgical resection were enrolled in this phase II study. A total dose of 64.0 GyE in 16 fractions over 4 weeks was indicated for 15 lesions, that of 70.4 GyE for 276 and remaining 10 receiving 73.6 GyE. Mean age was 52 yrs, (range 12-85); site of origin was the pelvis in 74%, spine or para-spinous soft tissue in 20%, extremities in 5%: bone primary was in 78% and soft tissue in 22%; pathologic subtype in bone sarcoma was chordoma in 42%, chondrosarcoma in 21%, osteosarcoma in 21%; pathologic subtype in STS was MFH in 23%, MPNST in 21%, synovial sarcoma in 13%. Results: The 3- and 5-year overall actuarial survival rates were 68% (95% Cl, 61%-75%) and 52% (95% C1, 43%-61%), respectively, and the actuarial overall local control rates were 85% (95% C1, 80%- 90%), and 81% (95'%C1, 74%-88%) at 3 years and 5 years of follow-up, respectively. Overall toxicity was acceptable, with 2% skin/soft tissue late G3/4 toxicity. Conclusions: Carbon ion radiotherapy shows a substantial local control in the patients with bone and soft tissue sarcomas not suited for surgical resection with acceptable morbidity. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | 44th ASCO Annual Meeting | |||||
発表年月日 | ||||||
日付 | 2008-06-03 | |||||
日付タイプ | Issued |